Diasome’s HDV-Insulin for T1D Finalizing Phase III Plans After Promising Data
HDV is intended to address the difficulty of insulin, GLP-1, or other molecules traveling to the liver when injected subcutaneously, due to the large number of receptors in peripheral tissue such as fat cells and muscle cells.